ArticleFolia microbiologica2026
Marine Bacillus safensis DJ1 metabolites disrupt P. aeruginosa virulence: an integrated experimental and network pharmacology and dynamics approach.
Article in Folia microbiologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Marine bioactive compounds are natural products known for diverse biological activities, including strong anti-quorum sensing (QS) properties. These compounds offer potential for developing antivirulence agents against pathogenic bacteria. Eighty-six bacterial isolates from the coastal region of Gujarat were screened for their ability to inhibit QS and virulence factors in Chromobacterium violaceum MK and Pseudomonas aeruginosa PA14. Isolate DKGJ2E6 (E6) (Bacillus safensis DJ1, identified by 16S rRNA sequencing) showed the strongest QS inhibitory activity and was selected for further analysis. The crude extract of Bacillus safensis DJ1 significantly inhibited key virulence traits in Pseudomonas aeruginosa, drastically reducing pyocyanin production and attenuating pyoverdine and biofilm formation. A similar anti-QS effect was observed in C. violaceum, where violacein production was more than halved (55.06% reduction). The extract also exhibited synergistic anti-virulence activity when combined with ciprofloxacin. Chemical profiling via GC-MS identified bioactive components such as sulfanilamide, indole, phenol, 3-methyl-4-oxo-pentanoic acid, and allantoic acid, which demonstrated potent anti-QS and antibiofilm effects. A network pharmacology approach was employed to predict and assess the molecular mechanisms, identifying core targets and target-pathway modulated by these metabolites. Molecular docking and dynamics demonstrated strong binding affinities of selected compounds towards key targets in Pseudomonas aeruginosa. Together, these findings collectively establish the potential of B. safensis DJ1 metabolites as a significant lead for the development of novel, marine-derived antivirulence therapies against drug-resistant pathogens.
Indexed as
Identifiers
41806182What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.